Amalgamated Valuation > Dilution ConcernsSo in my conversations with Dan, the real value is the IP and patents that are in the holding company.
I know for a fact that ATB-346, ATB-352, ATB-340 are the tip of the iceberg and these guys have patent rights for a whole lot more. They have IP rights to agents for Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis) in the holding company (ATB-429 - Mesalamine analog) and I've heard internally the suspected efficacy. How are they going to monetize the patent rights? Likely part of the entire partnership package.
This might sound like a joke to most people that are not in the know, but I agree with Mugs that the net value of the holding company patents + proof of concept from the 2A/2B trials should be north of $10B and could be in the range of $50B.
Bottom line, if you understand how to make new molecules for patenting, Antibe Holdings likely has a every NSAID known to man + H2S in there, and with my comment on ATB-429 (Mesalamine), it shows you they may have added H2S to a whole LOT more than NSAIDS where there's less of a concern about GI safety and more about superiority of efficacy with the addition of a hydrogen sulfide moiety based strictly on deficiencies and needs identified in medicine where there's a clear need.
I love this announcement. Can't believe people can still get in at this price, where the pre-Phase 2 risk is all gone but pretty close to the same price.
Do your own DD. GLTA and to all the longs, good times are definitely ahead. To me, this is the first sign that a partnership is perhaps closer than we think.